Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CELLDEX THERAPEUTICS, INC.

(CLDX)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
46.09 USD   +2.47%
02/03Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023
AQ
2022Insider Sell: Celldex Therapeutics
MT
2022Transcript : Celldex Therapeutics, Inc. - Special Call
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA-2LEN Global Urticaria Forum (GUF) 2022

12/05/2022 | 10:03am EST

HAMPTON, N.J. - Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that multiple presentations from the barzolvolimab development program will be presented at the 6th GA2LEN Global Urticaria Forum (GUF) being held December 7-8 in Berlin, Germany. Abstracts will be available on the meeting website on December 6th.

Presentations at GUF 2022 are outlined below and include new data from both the Phase 1b 1.5 mg/kg cohort conducted in cold urticaria and long term follow data from the Phase 1b 3.0 mg/kg cohorts conducted in cold urticaria and symptomatic dermographism. The chronic spontaneous urticaria (CSU) and wound healing presentations are Encore presentations and do not include new data.

WEDNESDAY, December 7, 2022

Oral: 'Cold urticaria patients achieve complete response with 1.5 mg/kg barzolvolimab' - Session III: Urticaria treatments and predictors of response | 18:07-18:16 CET

THURSDAY, December 8, 2022

Poster: 'Barzolvolimab-induced response and mast cell suppression are durable and linked' | 10:00 to 11:10 CET

ENCORE Oral: 'Multi-dosed barzolvolimab is effective in chronic spontaneous urticaria' - Session IV: Treatment of urticaria | 09:05-09:14 CET

ENCORE Poster: Mast cell reduction does not impair human cutaneous wound healing

Webcast and Conference Call

The Company will host a conference call/webcast to discuss the data at 8:00 a.m. ET on Tuesday, December 6. The event will be webcast live and can be accessed by going to the 'Events & Presentations' page under the 'Investors & Media' section of the Celldex Therapeutics website at www.celldex.com.

About Celldex Therapeutics, Inc.

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

Contact:

Sarah Cavanaugh

Senior Vice President

Corporate Affairs & Administration

T: (508) 864-8337

E: scavanaugh@celldex.com

Patrick Till

Meru Advisors

T: (484) 788-8560

E: ptill@meru.com

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about CELLDEX THERAPEUTICS, INC.
02/03Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results ..
AQ
2022Insider Sell: Celldex Therapeutics
MT
2022Transcript : Celldex Therapeutics, Inc. - Special Call
CI
2022Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chroni..
AQ
2022Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1B Study in Chroni..
CI
2022Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at..
AQ
2022Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at..
AQ
2022Guggenheim Adjusts Price Target on Celldex Therapeutics to $63 From $68, Maintains Buy ..
MT
2022Celldex to Participate in Upcoming November Investor Conferences
AQ
2022Celldex : Q3 Earnings Snapshot
AQ
More news
Analyst Recommendations on CELLDEX THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 0,99 M - -
Net income 2022 -113 M - -
Net cash 2022 298 M - -
P/E ratio 2022 -19,4x
Yield 2022 -
Capitalization 2 171 M 2 171 M -
EV / Sales 2022 1 895x
EV / Sales 2023 1 411x
Nbr of Employees 133
Free-Float 99,7%
Chart CELLDEX THERAPEUTICS, INC.
Duration : Period :
Celldex Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLDEX THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 46,09 $
Average target price 64,33 $
Spread / Average Target 39,6%
EPS Revisions
Managers and Directors
Anthony S. Marucci President, Chief Executive Officer & Director
Sam Martin CFO, Secretary, Treasurer & Senior Vice President
Karen Lipton Shoos Chairman
Tibor Keler Chief Scientific Officer & Executive VP
Diane C. Young Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
CELLDEX THERAPEUTICS, INC.0.92%2 171
MODERNA, INC.-1.82%66 559
LONZA GROUP AG21.92%44 368
IQVIA HOLDINGS INC.15.76%44 054
ALNYLAM PHARMACEUTICALS, INC.-3.32%28 711
SEAGEN INC.7.38%25 622